Copertina

Letter: Methodological Considerations in Comparing Liver Outcomes of Glucagon‐Like Peptide‐1 Receptor and Sodium Glucose Cotransporter‐2 Inhibitors

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Cheng‐Hsien Hung, Chun‐Ting Lin, James Cheng‐Chung Wei
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
di: Kuan‐Ju Lin, et al.
Pubblicazione: (2025)

Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
di: Chia‐Chih Kuo, et al.
Pubblicazione: (2025)

Some Risks of Gastrointestinal Adverse Events Associated With Glucagon‐Like PEPTIDE‐1 Receptor Agonists Are Likely Explained by BMI
di: Benjamin Douglas Liu, et al.
Pubblicazione: (2025)

Editorial: Immune Checkpoint Inhibitors and HBV Reactivation in Liver Cancer—Reassurance With Vigilance
di: Romeo Kuo‐Cheng Wu, et al.
Pubblicazione: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Letter: Dynamic HBcrAg and HBsAg After Nucleos(t)ide Analogue Cessation: Considerations in Interpreting Predictive Performance
di: Hsiang‐Ting Keng, et al.
Pubblicazione: (2026)

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
di: Mazen Noureddin, et al.
Pubblicazione: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR
di: Zhejin Shi, et al.
Pubblicazione: (2026)

Letter: Optimising Targeted Next‐Generation Sequencing for Intestinal Tuberculosis Diagnosis—Methodological Considerations
di: Haleema Rahman
Pubblicazione: (2025)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
di: Yuki Utakata, et al.
Pubblicazione: (2026)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
di: Yi‐Ping Hung, et al.
Pubblicazione: (2024)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Considerations for Outcome Measurement and Clinical Interpretation
di: Dingsheng Liu, et al.
Pubblicazione: (2025)

Letter: Impact of HCV Eradication on Recurrence Pattern and Long‐Term Outcomes in Patients With HCV‐Related Hepatocellular Carcinoma Undergoing Radiofrequency Ablation. Authors' Reply
di: Kuo‐Cheng Wu, et al.
Pubblicazione: (2024)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
di: Xinglin Li, et al.
Pubblicazione: (2026)

Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
di: Maryam Zafer, et al.
Pubblicazione: (2025)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
di: Isabella Lurje, et al.
Pubblicazione: (2025)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
di: Yee Hui Yeo, et al.
Pubblicazione: (2026)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations
di: Christophe Corpechot
Pubblicazione: (2026)

Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor
di: Shoko Miyahara, et al.
Pubblicazione: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
di: Ryan Yanzhe Lim, et al.
Pubblicazione: (2026)

Letter: Re‐Examining Seton Efficacy in Perianal Crohn's Disease—Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply
di: Jeffrey D. McCurdy, et al.
Pubblicazione: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
di: Jiru Li, et al.
Pubblicazione: (2025)

Letter: Toward Intra‐Class Switching With JAK Inhibitors?
di: Mathieu Uzzan, et al.
Pubblicazione: (2025)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Letter: Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor: Authors' Reply
di: Kee Huat Chuah, et al.
Pubblicazione: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
di: J. M. Schattenberg, et al.
Pubblicazione: (2026)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
di: Muhammad Osama, et al.
Pubblicazione: (2024)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
di: Mohamed El‐Kassas, et al.
Pubblicazione: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
di: Jee‐Fu Huang, et al.
Pubblicazione: (2026)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
di: Shintaro Akiyama, et al.
Pubblicazione: (2025)

Letter: Exclusive Enteral Nutrition in Ulcerative Colitis—The Path Ahead Needs Careful Consideration
di: Sarah Melton, et al.
Pubblicazione: (2025)

Liver Fibrosis and the Risk of Coronary Artery Disease, Stent Thrombosis, Restenosis and Adverse Clinical Outcomes
di: Na Tian, et al.
Pubblicazione: (2025)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
di: Jia‐Yong Su, et al.
Pubblicazione: (2025)

Letter: From Safety to Precision—Optimising the Use of GLP‐1 Receptor Agonists in Gastroenterology
di: Joëlle St‐Pierre, et al.
Pubblicazione: (2026)

Editorial: Checkpoint Inhibitor‐Induced Liver Injury—Time to Abandon CTCAE?
di: Kelly Torosian, et al.
Pubblicazione: (2024)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
di: Rong‐Xiang Ng, et al.
Pubblicazione: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
di: Nina Dominik, et al.
Pubblicazione: (2024)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
di: Zhanbo Qu
Pubblicazione: (2026)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
di: Chachrit Khunsriraksakul, et al.
Pubblicazione: (2025)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease
di: Qiong Yi, et al.
Pubblicazione: (2024)